Viking Therapeutics' second quarter 2026 loss per share beats estimates as its Phase 3 obesity trials advance.

Viking Therapeutics reported a smaller-than-expected loss for the second quarter as key clinical trials for its obesity drug candidate, VK2735, progressed as planned.

Key Highlights

• Reported a net loss of $1.10 per share, beating analyst estimates for a loss of $1.21 per share.
• Research and development expenses were $115.8 million, lower than the $145.0 million consensus estimate, contributing to the smaller loss.
• Confirmed its Phase 3 VANQUISH trials for subcutaneous VK2735 are fully enrolled and expects to initiate the oral Phase 3 trial in the fourth quarter of 2026.
• Ended the quarter with a strong cash, cash equivalents and short-term investments position of $502 million.